Loading…
enVVeno Medical Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in NVNO.
▼ -97.2% over 5Y.
today you would have $23.86▼ -97.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $11.23 | $105.70 | $179.90 | $178.50 | $230.65 | $302.75 | $481.25 | $1,290.63 | |
| P/S | — | — | — | — | — | — | — | 338.6x | 112.0x |
| P/B | 1.4x | 0.3x | 1.3x | 1.5x | 1.2x | 1.1x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CELZCreative Medical Technology Holdings Inc | $1.14 | — | 0.9x | — | -77.88% | $7.52M |
| INMInMed Pharmaceuticals Inc. | $1.38 | — | 0.7x | — | -112.65% | $7.37M |
| CANFCan-Fite BioPharma Ltd. | $3.40 | — | 0.8x | — | -178.24% | $7.28M |
| ENSCEnsysce Biosciences, Inc. | $0.40 |
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Company description provided by Yahoo Finance.
| 10.4x |
| 10.7x |
| 10.3x |
| EPS | -$33.06 | -$44.53 | -$66.85 | -$77.00 | -$66.50 | -$263.90 | -$423.50 | -$1,531.25 |
| Profit margin | — | — | — | — | — | — | — | -24406.74% | -6991.46% |
| ROE | -67.73% | -71.77% | -51.75% | -50.90% | -63.70% | -30.38% | -128.71% | -770.29% | -640.47% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -1295.09% |
| $7.78M |
| CURXCuranex Pharmaceuticals Inc | $4.56 | — | 1.4x | — | -411.08% | $7.15M |
| BOLTBolt Biotherapeutics, Inc. | $3.71 | — | 0.6x | — | -111.65% | $7.15M |